Can a short immunotherapy course shrink early breast tumors before surgery?
NCT ID NCT05215106
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study looks at whether the tumor disappears completely and how safe the treatment is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (an immunotherapy drug given intravenously)
- What this could lead to
- If effective, this approach could offer a new treatment option for early triple negative breast cancer, potentially improving outcomes before standard surgery.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The drug may not improve response rates, and immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY SMALL (CT1N0) TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Léon Berard
Lyon, France
-
Gustave Roussy
Villejuif, 94805, France
-
Institut Bergonié
Bordeaux, France